Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Purple Biotech Ltd. (PPBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Purple Biotech files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with registration statements on Forms F-1, F-3 and S-8, outline the company’s clinical-stage oncology strategy, financing activities, and corporate actions.
Through its Form 6-K reports, Purple Biotech furnishes press releases and corporate presentations that describe its oncology pipeline, including the CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219. Filings reference milestones such as manufacturing achievements for IM1240, preclinical and clinical data updates, European patent developments for NT219 combinations, and collaborations with academic institutions. They also include financial results, at-the-market offering agreements, and details of public offerings of American Depositary Shares and warrants.
Investors use Purple Biotech’s SEC filings to review quarterly and interim financial information furnished on Form 6-K, as well as capital markets transactions such as shelf registrations on Form F-3 and follow-on offerings. The filings also document corporate governance events, including notices and results of shareholder meetings, and incorporate certain reports by reference into existing registration statements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on pipeline progress, financing terms, and listing compliance matters. Users can follow new 6-K submissions in near real time as they are posted to EDGAR, and then drill into specific exhibits such as press releases or corporate presentations for more detail.
For those researching PPBT, this page serves as a central location to review Purple Biotech’s official SEC communications related to its clinical programs, financial position, and securities offerings, all organized chronologically with concise AI-generated overviews.
Purple Biotech Ltd. reports that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement. Nasdaq’s Listing Qualifications Department confirmed that the company now meets Nasdaq Listing Rule 5550(a)(2) for continued listing.
To regain compliance, Purple Biotech’s American Depositary Shares maintained a minimum closing bid price of at least $1.00 per share for 10 consecutive business days, a condition achieved on March 13, 2026. The company continues to develop its next-generation immunotherapy platform, including lead candidates IM1240 and IM1305 and other oncology assets.
Purple Biotech Ltd. reported a much wider full-year 2025 net loss of $26.4 million, driven mainly by a $20.5 million non-cash impairment of its CM24 and NT219 programs as it shifts focus to its CAPTN-3 tri-specific antibody platform.
Adjusted operating loss improved to $6.7 million from $10.4 million in 2024, reflecting lower clinical trial spending, while research and development expenses fell to $3.7 million from $7.6 million. Cash, cash equivalents and deposits totaled about $9.5 million as of December 31, 2025, which the company expects to fund operations into 2027.
The lead CAPTN-3 candidate IM1240 achieved toxicology and manufacturing milestones, and IM1305 was named a development candidate. Separately, CEO Gil Efron will step down in August 2026 for health reasons, remaining on the board and leading corporate development while a search for a new CEO is underway.
Purple Biotech Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS for 200 ordinary shares to one ADS for 2,000 ordinary shares. Trading reflecting the new ratio is expected to begin on or about March 2, 2026.
For ADS holders, this acts as a one-for-ten reverse ADS split: every 10 existing ADSs will be exchanged for 1 new ADS, with no action needed for uncertificated holders. Fractional ADSs will be sold by the depositary, and net cash from those fractions will be distributed to holders.
The move is primarily intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The ADSs will keep the “PPBT” symbol and receive a new CUSIP. The ratio change does not affect the company’s ordinary shares on the Tel Aviv Stock Exchange.
Susquehanna Securities, LLC filed a Schedule 13G reporting beneficial ownership of 93,953,400 Ordinary Shares of Purple Biotech Ltd., equal to 5.2% of the class. The position is held through 469,767 ADSs, with each ADS representing 200 Ordinary Shares.
Based on the company’s disclosure that 1,806,089,801 Ordinary Shares were outstanding as of October 20, 2025, Susquehanna’s holdings represent a significant but minority passive stake. The filing states the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Purple Biotech.
Purple Biotech Ltd. submitted a Form 6-K as a foreign private issuer to furnish an updated corporate presentation titled “Purple Biotech Corporate Presentation January 2026.” This presentation is included as Exhibit 99.1 and is intended to provide current information about the company in January 2026.
The report is formally authorized on behalf of Purple Biotech Ltd. and is signed by Chief Executive Officer Gil Efron, dated January 12, 2026.
Purple Biotech Ltd. reported a key preclinical milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform, in a non-human primate toxicology study. IM1240’s proprietary CD3 capping design enabled dosing up to 300-fold higher than a non-capped comparator, with markedly reduced immune-related toxicity and minimal cytokine release, suggesting a wider safety margin than certain current T cell engagers. The study also showed a favorable pharmacokinetic profile, with increased systemic exposure and a prolonged circulating half-life linked to its human serum albumin moiety and capping design. Purple Biotech plans to advance IM1240 toward first-in-human clinical trials, with a regulatory submission targeted for the second half of 2026, while continuing to develop its broader oncology pipeline, including CAPTN-3 candidates IM1240 and IM1305, and clinical-stage assets CM24 and NT219.
Purple Biotech Ltd. reports that shareholders approved all proposals presented at its Extraordinary General Meeting held on December 15, 2025 at the company offices in Rehovot, Israel. The proposals were described in the company proxy statement furnished on October 28, 2025 and received the requisite votes under Israeli Companies Law and the company articles of association.
The company also states that this Form 6-K, including its exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, so those offering documents now include these meeting results.
Purple Biotech Ltd. filed a Form 6-K to notify investors that it has released an updated corporate presentation titled “Purple Biotech Corporate Presentation November 2025.” The presentation is furnished as Exhibit 99.1. This type of filing is mainly informational, giving the market updated background on the company and its activities rather than announcing a specific transaction or new financial results.
Purple Biotech Ltd. furnished a Form 6-K announcing that, on November 14, 2025, it issued a press release titled “Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update,” attached as Exhibit 99.1.
The Form 6-K, including all exhibits, is incorporated by reference into the company’s existing Form F-3 and Form S-8 registration statements, making it part of those filings from the date of submission, to the extent not superseded by later reports.
Purple Biotech Ltd. furnished a Form 6-K noting it issued a press release titled “Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform.” The press release is included as Exhibit 99.1 and is dated October 29, 2025.
The filing is administrative and points readers to the attached press release for details on the IM1240 manufacturing milestone from the CAPTN-3 platform.